Core Viewpoint - Emergent BioSolutions Inc. has authorized a stock repurchase program of up to $50 million, reflecting confidence in its strategy and future outlook while aiming to create long-term value for shareholders [1][2]. Company Overview - Emergent BioSolutions has approximately 54.3 million shares of common stock outstanding as of December 31, 2024 [3]. - The company focuses on delivering protective and life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]. Stock Repurchase Program - The stock repurchase may occur on the open market or through privately negotiated transactions, with timing and amount determined by management based on market conditions and other factors [2]. - The program is part of the company's multi-year transformation plan aimed at driving long-term growth and profitability [2].

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan"). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the "Equity A ...

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depres ...

Core Insights - Emergent BioSolutions Inc. has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million, subject to customary post-closing adjustments [1][2] - The sale allows Emergent to streamline operations while retaining rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene [2][3] - The CEO of Emergent stated that this deal positions the company well for executing turnaround initiatives and driving sustainable, long-term growth [3] Company Overview - Emergent BioSolutions has been active for over 25 years, focusing on delivering protective and life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]

Core Insights - Emergent BioSolutions Inc. has secured approximately $27 million in international orders for its medical countermeasures (MCM) portfolio, aimed for delivery in 2025, addressing threats like smallpox and anthrax [1][2] - The company emphasizes its role as a trusted partner in supplying medical countermeasures globally, supporting health preparedness efforts [2] - Emergent is focused on international expansion and strengthening health preparedness as part of its multi-year transformation plan [2][3] Company Overview - Emergent BioSolutions has over 25 years of experience in preparing for public health threats, providing solutions for various health emergencies including smallpox, anthrax, and Ebola [3] - The company aims to protect and save lives by delivering life-saving solutions and enhancing community preparedness against health challenges [3] Market Position - The types and quantities of medical countermeasures maintained in stockpiles depend on population needs, available products, and government resources [2]

Core Insights - Emergent BioSolutions Inc. is enhancing partnerships to improve opioid emergency preparedness as overdose death rates decline for the first time in five years [1] - The company is focusing on expanding access to NARCAN® Nasal Spray and educating the public on responding to opioid overdoses [1][2] Group 1: NARCAN® Nasal Spray Initiatives - NARCAN® Nasal Spray is the first FDA-approved over-the-counter naloxone product for emergency opioid overdose treatment [2][6] - Emergent is collaborating with the NYC Building & Construction Industry Safety Fund to launch the HOPE/LIVES educational program, which trains construction workers on recognizing opioid overdoses and administering NARCAN® [2] - Each construction worker will receive an opioid emergency kit containing two doses of NARCAN® to prepare for emergencies [2] Group 2: Partnerships and Community Support - Emergent is working with Pathway Healthcare to provide NARCAN® Nasal Spray at its Mississippi locations, enhancing safety for patients affected by opioid use disorder [3][4] - Pathway Healthcare emphasizes the importance of making naloxone readily available in clinics to provide immediate support to at-risk individuals [4] - The initiative aims to create a supportive environment for patients and their families, reducing stigma around seeking help [5] Group 3: Industry Impact and Advocacy - The decline in opioid overdose deaths highlights the effectiveness of increased education and access to naloxone [5] - Emergent BioSolutions advocates for a united effort among various stakeholders, including advocacy groups and government officials, to combat opioid overdose deaths [5] - The company aims to ensure that every individual and venue is prepared to respond to opioid emergencies [5]

Core Insights - Emergent BioSolutions Inc. has entered into a strategic financial investment agreement with Rocketvax Ltd to support research and development in biotechnology [1][2] - The partnership will focus on U.S. manufacturing and commercialization of four pipeline candidates targeting infectious diseases, cancer, and autoimmune disorders [2] - Rocketvax's leading candidate is a live-attenuated nasal spray SARS-CoV-2 vaccine, showing superior efficacy compared to mRNA vaccines in animal studies [3] Company Overview - Emergent BioSolutions is a public health company dedicated to delivering protective and life-saving solutions for various health threats, including smallpox and Ebola [5] - Rocketvax Ltd specializes in next-generation vaccines using proprietary molecular biology technologies, aiming to enhance vaccine stability and distribution [6] Strategic Goals - The collaboration aims to accelerate the development of innovative products addressing significant public health challenges, aligning with Emergent's multi-year transformation plan [4] - The partnership is expected to revolutionize disease prevention and immunotherapy, providing life-saving solutions globally [4]

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lin ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were $195 million, a decrease compared to the previous year due to lower NARCAN sales and Amtrac sales timing, partially offset by an adjusted EBITDA of $21 million, which is an increase of $18 million year-over-year [27] - Full-year 2024 total revenues were approximately $1.04 billion, roughly flat compared to the prior year, with total adjusted EBITDA of $183 million, a significant improvement from a negative $22 million in 2023 [29] - Operating expenses for the full year were $379 million, down $101 million or 21% year-over-year, reflecting cost actions taken in the second half of 2024 [30] Business Line Data and Key Metrics Changes - Total product sales for 2024 were $909 million, a slight decline from the previous year, with increased smallpox revenue offset by lower NARCAN sales [30] - NARCAN maintained a competitive price and market-leading distribution capabilities, with full-year volume consistent with 2023 levels, although prices were lower compared to 2023 [31] Market Data and Key Metrics Changes - The company distributed 11 million two-dose cartons (22 million doses) of NARCAN across the US and Canada, maintaining a market leadership position in the growing naloxone nasal spray market [18] - The naloxone market is expected to grow by mid to high single-digit rates, with NARCAN holding approximately 75% market share [50] Company Strategy and Development Direction - The company is executing a multi-year transformational plan aimed at stabilizing and ultimately transforming the business to generate long-term profitable growth [14] - Key goals for 2025 include strong profit follow-through from 2024, rebuilding the product pipeline, optimizing manufacturing operations, and strategic capital deployment for growth opportunities [20] Management's Comments on Operating Environment and Future Outlook - Management expressed a conservative approach to 2025 guidance due to potential shifts in government administration and timing uncertainties [22] - Despite a conservative outlook, management anticipates a strong first quarter of 2025, supported by the momentum from 2024 [40] Other Important Information - The company secured $550 million in MCM contract awards in 2024 and resolved legacy legal and quality issues, improving quality and compliance systems [19] - The company has a total liquidity of $200 million at the end of 2024, with net debt reduced to $601 million, a 21% decrease since the beginning of 2024 [36] Q&A Session Summary Question: Can you provide specifics on NARCAN guidance regarding volume and price? - Management noted that pricing stabilized in the second half of 2024, but a follow-through impact from previous price reductions is expected to affect full-year results [67][69] Question: How do you see adjusted EBITDA evolving in 2026 and beyond? - Management indicated that growth opportunities exist through diversification of the product portfolio and additional business development efforts [72][76] Question: What is the outlook for Kloxado in the market? - Management plans to leverage existing distribution capabilities to facilitate Kloxado's market entry and expects it to complement NARCAN in addressing fentanyl overdoses [84][86] Question: Is Kloxado already available within the NARCAN direct system? - Management confirmed that logistics are being worked out and expects Kloxado to be available within 30 to 60 days [93] Question: What are the expectations for near-term contract adjustments for BioDefense products? - Management anticipates continued execution of contracts and procurement orders from the US government, similar to the patterns seen in 2024 [99]

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were $195 million, a decrease compared to the prior year due to lower NARCAN sales and Amtrac sales timing, partially offset by adjusted EBITDA of $21 million, an increase of $18 million year-over-year [27] - Full-year 2024 total revenues were approximately $1.04 billion, roughly flat compared to the prior year, with total adjusted EBITDA of $183 million, a positive swing of $205 million from a negative $22 million in 2023 [29] - Total adjusted gross margin for 2024 was $457 million, an annual improvement of $121 million or 1200 basis points as a percentage of revenue [29] Business Line Data and Key Metrics Changes - Total product sales for 2024 were $909 million, a slight decline from the prior year, with increased smallpox revenue offset by lower NARCAN sales [30] - NARCAN maintained a competitive price and market-leading distribution capabilities, with full-year volume consistent with 2023 levels [31] - The company achieved $130 million in reduced operating expenditures while meeting core product commitments [17] Market Data and Key Metrics Changes - Emergent BioSolutions distributed 11 million two-dose cartons (22 million doses) of NARCAN across the US and Canada in 2024, maintaining a leading market share in the growing naloxone nasal spray market [18] - The company secured $550 million in medical countermeasure (MCM) contract awards in 2024, supporting public health preparedness [19] Company Strategy and Development Direction - The company is executing a multi-year transformational plan aimed at stabilizing and ultimately transforming the business to generate long-term profitable growth [14] - Key goals for 2025 include strong profit follow-through from 2024, rebuilding the product pipeline, optimizing manufacturing operations, and strategic capital deployment for growth opportunities [20] - The company is focused on addressing public health threats and expanding access to NARCAN, with plans to leverage its distribution capabilities for Kloxado nasal spray [53][84] Management's Comments on Operating Environment and Future Outlook - Management expressed a conservative approach to 2025 guidance due to potential shifts in government administration and timing uncertainties [22] - Despite a conservative outlook, management anticipates a strong first quarter of 2025, supported by the momentum from 2024 [100] - The company is optimistic about the potential for growth in its MCM products and the ongoing support for biodefense initiatives [55] Other Important Information - The company completed $117 million in asset sales and received a $50 million payment from Janssen Pharmaceuticals as part of a settlement agreement [33] - Total liquidity at the end of 2024 was $200 million, with net debt reduced by $156 million or 21% since the beginning of 2024 [36] Q&A Session Summary Question: Can you provide specifics on NARCAN guidance regarding volume and price? - Management noted that pricing stabilized in the second half of 2024, but a follow-through impact from prior reductions is expected to affect full-year results [67][68] Question: How do you see adjusted EBITDA evolving in 2026 and beyond? - Management indicated that diversification of the business and additional organic opportunities will contribute to growth in adjusted EBITDA, but specifics for 2026 were not provided [72][76] Question: What is the outlook for Kloxado's market positioning? - Management plans to leverage existing distribution capabilities to facilitate access to Kloxado, particularly in response to increasing fentanyl overdoses [84][86] Question: Is Kloxado already available within the NARCAN direct system? - Management confirmed that logistics are being worked through, with expectations for Kloxado to be available in the next 30 to 60 days [93][94] Question: What are the expectations for near-term contract adjustments for BioDefense products? - Management expects the US government to continue executing contracts and issuing procurement orders throughout 2025, following the pattern established in 2024 [99]